HIV/AIDS Clinical Trials

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

Condition: HIV Infections

NCT ID: NCT00056797

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

Condition: HIV Infections

NCT ID: NCT00183261

Active, not recruiting(En español)

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Condition: HIV Infections

NCT ID: NCT01266616

ITV Extension Study

Condition: HIV

NCT ID: NCT00332930

Phase I/IIa Dose-escalation Clinical Study of VAC-3S

Condition: HIV-1 Infection

NCT ID: NCT01549119

Active, not recruiting

Dendritic Cell Vaccine in HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00402142

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT01428596

Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects

Condition: HIV Infections

NCT ID: NCT01029548

Terminated

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

Condition: HIV Infections

NCT ID: NCT00107549

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00050063

Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine (ISS T-002)

Condition: HIV Infections

NCT ID: NCT00751595

Screening HIV-Infected Patients for Vaccine Studies

Condition: HIV Infection

NCT ID: NCT00051519

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

Condition: HIV Infection

NCT ID: NCT00001445

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

Condition: Acquired Immunodeficiency Syndrome; HIV Infection

NCT ID: NCT00001386

Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

Condition: HIV Infection

NCT ID: NCT00219362

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000809

Withdrawn

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000774

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

Condition: HIV Infections; Pregnancy; HIV Seronegativity

NCT ID: NCT00001046

Withdrawn

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000879

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

Condition: HIV Infections; Pregnancy; HIV Seronegativity

NCT ID: NCT00000777

Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT01082692

Autologous Dendritic Cell Vaccine in HIV1 Infection

Condition: HIV Infections

NCT ID: NCT00510497

Active, not recruiting

Analysis of Immune Responses to HIV Vaccines

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT00068978

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

Condition: HIV Infections

NCT ID: NCT00021762

Withdrawn(En español)

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

Condition: HIV Infections

NCT ID: NCT00011011

Active, not recruiting(En español)

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

Condition: HIV Infections

NCT ID: NCT00006509

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

Condition: HIV Infections

NCT ID: NCT00000633

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

Condition: HIV

NCT ID: NCT00270465

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00056758

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00052182

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

Condition: HIV Infections

NCT ID: NCT00125099

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Condition: HIV Infections

NCT ID: NCT00001060

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

Condition: HIV Infections

NCT ID: NCT00000977

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

Condition: HIV Infections

NCT ID: NCT00117429

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Condition: HIV Infections

NCT ID: NCT00000762

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Condition: HIV Infections

NCT ID: NCT00000822

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

Condition: HIV Infections

NCT ID: NCT00005779

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

Condition: HIV Infections; Pregnancy

NCT ID: NCT00001041

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00080106

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

Condition: HIV Infections

NCT ID: NCT00006495

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

Condition: HIV Infections

NCT ID: NCT00005758

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

Condition: HIV Infections

NCT ID: NCT00000958

Not yet recruiting(En español)

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

Condition: HIV Infections

NCT ID: NCT00006153

Terminated(En español)

Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults

Condition: HIV Infections

NCT ID: NCT00614640

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Condition: HIV Infections

NCT ID: NCT00000943

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Condition: HIV Infections

NCT ID: NCT00006291

Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS

Condition: HIV Infections

NCT ID: NCT00505401

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

Condition: HIV Infections

NCT ID: NCT00390078

A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV

Condition: HIV Infections

NCT ID: NCT00529971

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

Condition: HIV Infections

NCT ID: NCT00000667

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

Condition: Tuberculosis; HIV Infections

NCT ID: NCT00395720

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00058734

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

Condition: HIV Infections

NCT ID: NCT00000782

Efficacy Study of T Cell Vaccination in HIV Infection

Condition: HIV Infections

NCT ID: NCT00407836

Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy

Condition: HIV Infections

NCT ID: NCT00991224

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Condition: HIV Infections

NCT ID: NCT01092611

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Condition: HIV Infections

NCT ID: NCT00000755

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Condition: HIV Infections

NCT ID: NCT00013663

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Condition: HIV Infections

NCT ID: NCT00000779

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

Condition: HIV Infections

NCT ID: NCT00001121

Novel Interventions in HIV-1 Infection

Condition: HIV-1 Infection

NCT ID: NCT01130376

Terminated

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

Condition: HIV Infections

NCT ID: NCT00026624

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

Condition: Human Immunodeficiency Virus

NCT ID: NCT00488995

Withdrawn

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine

Condition: HIV Infections

NCT ID: NCT00238459

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

Condition: HIV-1 Infection

NCT ID: NCT01627678

Observational Study on Anti-tat Immune Response in HIV-1-infected HAART-treated Adult Subjects

Condition: HIV Infection

NCT ID: NCT01024556

Terminated

HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease

Condition: Aids, Cdc Group I

NCT ID: NCT01141205

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

Condition: HIV Infection

NCT ID: NCT01473810